Bharat Book Bureau

This report is an essential source for data, analysis and strategic insight into Accuray Incorporated. The report provides key information relating to market share by sector and country, financial, SWOT and value chain analysis of the company. The report examines company’s business structure and operations, history and products, and provides an analysis of its key revenue lines. It inspects the company’s strategy, both in terms of its value chain positioning and strategic strengths and weaknesses.

Scope:-

 Revenues for the markets and sub-sectors Accuray Incorporated operates in by country and region.
 Detailed breakdowns of revenues and market share benchmarked against competitors.
 Profiles of the pipeline of products that the company is developing.
 Critical analysis of the company’s strengths, weaknesses opportunities and threats and positioning on the value chain.
 Provides summary analysis of key revenue lines and strategy.
 Details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
 Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions.
 Latest mergers and acquisitions, partnerships or financings of the company, including debt, equity or venture finance.

Reasons to buy:-

 A single source to fulfill all of your business and competitor intelligence needs
 Research your competitors business structure, strategy and prospects.
 Counter your competitors strengths and target their weaknesses.
 Identify your competitors key revenue streams by market and geography.
 Identify and assess potential corporate and investment opportunities
 Support sales activities by understanding your customers businesses better.
 Identify potential competitor products before they reach market.
 Qualify prospective partners and suppliers.
For more information,kindly visit - http://www.bharatbook.com/detail.asp?id=82988

Wouldn’t it be great if you could answer these 3 questions everytime?, Will a drug be successful?, Will a drug make any money?, Is it worth investing in a drugs’ further development?, In these days of thin pipelines and revenues consolidating into a few products there is high pressure your company’s product managers to be sure that their next product, if not a blockbuster, is at least a winner. However, you will be fully aware that through Pharmacoeconomics, we can go some way to predict the future success of your drug!

But questions still remain

Are Pharmacoeconomics any good?
Do Pharmacoeconomics work?
it’s’s brand new report, answers these questions for you. This new report examines the link between this new developmental tool, the financial success of drug and how decision makers are increasingly using Pharmacoeconomics to make their drug purchases - are you using Pharmacoeconomics successfully?

Currently there are 4 economic factors in a pharmacoeconomic evaluation :

Cost minimisation
Cost effectiveness analysis (CEA)
Cost benefit analysis (CBA)
Cost utility analysis (CUA)
it’s’s Pharmacoeconomics and Success in the Marketplace report, examines these steps and points out their usefulness in a drugs’ commercial viability and market positioning.

The report also tackles crucial issues such as :

Formulary decisions
The current effective structure of Pharmacoeconomics
Data problems in implementing and succeeding in Pharmacoeconomics
The influence of Pharmacoeconomics in the pharmaceutical R&D sector
Global Pharmacoeconomic practice from the major industry players

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44655
_______________________________________________________________

Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 13.0% to 2009.it’s’s latest report, ” The Global Ophthalmic Pharmaceutical Market 2004-2009 ” , explains just how this market will experience growth over the medium term future.

The world market is currently valued at $7.25bn and revenues are forecasts to rise to over $14bn in 2009. Do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what stratergies can be used to maxmise profits from the drivers and restraints? Ensure your organisation is successful in this market by reserving your copy of it’s’s report today.

According to the findings of the new 170+page report, it’s reveals that Glaucoma therapies are set to dominate the market over the forecast period (2002-2009), accounting for almost 40% of market revenues by 2009. Indeed, 2004 saw the first blockbuster drug of the market, used to treat glaucoma.

Find out who are the major companies involved in the ophthalmic world market today and in the future. And what R&D opportunities exist for ‘new-comers’ to the ophthalmic pharmaceutical market.

In the process of providing a thorough evaluation of the market, the it’s Ophthalmics report focuses on the major therapeutic areas of the market:
Glaucoma
AMD
Ocular Allergies
Dry Eye Syndrome
Ocular Infections
Ocular Inflammation
Do you know what the market values of these major therapeutic areas of the ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC ophthalmic drugs by disease and product type. The study also assess’s the challenges faced by ophthalmic companies, and what exciting market opportunites exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features over 50 tables, 30 graphs and charts, news, insights, the latest developments and an in depth survey of the ophthalmics market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company ‘the edge’ on your competitiors. You can not afford to be without this latest report from it’s.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44656
_______________________________________________________________

According to indepth analysis from Dr Ray Scraggs, Senior Pharmaceutical Industry Analyst with It the total value of the world market for antifungal medication, topical as well as systemic, was worth in 2003 nearly $6 billion. The report entitles The World Market for Antifungal Therapies 2004-2009 divides the total market into:

Systemic :

Topical OTC and Prescription
This is one of the few reports of this type on the market that attempts an analyses of both the systemic and topical markets.

Further the systemic market is subdivided into analyses that includes :
Azoles
Polyenes
Pyrimidines
Allylamines
Echinodians

According to Dr Scraggs the total market will see a growth rate decline with an average growth rate (AAGR) from 2002-2009 of only 39.1 per cent, revenues by 2009 will be approaching $8 billion. Systemic antifungals, not surprisingly dominate this market with a 60 per cent market share. This is a market you must become successful in.  There is a significant unmet need in this market because the present portfolio of treatments interact unfavourably with other medications, have resistance problems, low spectrum of activity, are fungistatic as opposed to fungicidal and are often toxic. The company that can arrive at a new class of drug that can overcome all these limitations will be guaranteed high profits.

Key Questions Answered in this Report :

Total revenues and growth rates for each market segment from 2002-2009
A list of the important drivers and restraints
Incisive market predictions for each segment and individual drug type
A market share analysis of each segment
New products and new developments
A review of the latest innovations in antifungal vaccine discovery
Analysis of market trends

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44659
_______________________________________________________________

The world vaccine market, once characterized by slow growth, has seen increased sales as a result of new paediatric vaccines and the burgeoning influenza vaccine markets in the U.S. and Europe. You should be taking advantage of this growth NOW!!. The adult market for vaccines is predicted to grow by 26.3 per cent in 2004, but what will it be in 2007 - only It’s unique report can tell you today.

In 2003 the world vaccine market is valued at over $5 billion, shouldn’t you be claiming an increased share of this market immediately.

Paediatric vaccines still hold the largest share of the overall market, but influenza and hepatitis vaccine sales have grown significantly over the past few years. Paediatric vaccines markets are growing at a slower rate than the adult market and you need to position your company correctly to ensure your continued success.

A large number of therapeutic vaccines under development prove to make the vaccine market an interesting and dynamic one over the next five years. Therapeutic vaccines are currently being tested against cancer and are approaching approval.

The Therapeutic and Prophylactic Vaccine Market 2003 provides in-depth analysis of the vaccine market, presents key findings that are driving the market, and contains up-to-date information regarding vital clinical trials, sales figures, and profiles of key vaccine companies.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44660
_______________________________________________________________

The combined value of the women’s reproductive health pharmaceutical market is currently over $20 billion. A positive growth rate of 8 per cent is expected per annum for the next five years, according to It Publishing of London. An expanded variety of contraceptive choices for women is driving growth, as is continued growth in the gonadotrophins class for infertility.

Negative press regarding the side effects associated with hormone replacement therapy (HRT) has slowed this market down slightly, leaving a vaccum of market share for other osteoporosis therapies. HRT will, however, rebound during the forecast period and re-achieve strong growth.

Women’s Reproductive Health 2004 is arranged to provide an overview of this complex market. Specific attention is given to the following areas:
Contraception
Infertility
Osteoporosis/Menopause
Analysis and financial forecasts in these markets take into account many factors including:
Consumer preference statistics
Product differentiation
New indications
Patent expirations
Generic competition
The Women’s Health Institute HRT Study
Emerging markets, eg. Japan
Detailed financial information and forecasting is also provided for each chapter including in-depth coverage of drugs in the infertility and osteoporosis drug markets such as:
Gonadotrophins
Bisphosphonates
Selective estrogen receptor modulators
GnRH Antagonists
Hormone replacement therapy
Detailed product differentiation and financial analysis is presented for the following contraceptive products:
Hormonal contraceptives
Intra-uterine devices
Transdermal patches
Depot contraceptives
Emergency contraception

Analysis includes the use of charts and graphs measuring product growth and trends within the women’s reproductive health marketplace. Company-specific information, including sales figures, drug pipeline status, and research and development trends is provided throughout the report. Five-year financial forecasts are also provided

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44661
_______________________________________________________________

One of the major problems in medical pharmacology is that a drug will not function to the same degree of efficacy in all patients. Often drugs will only exert the desired therapeutic effect in perhaps 30-70 per cent of patients. Anti-depressants, for example, are notorious for being successful in only 30 per cent of cases; the other 70 per cent are described as non-responders.
Furthermore drugs may function as predicted in one population of patients whilst in others it may lead to an adverse drug reaction (ADR). In the US it is estimated that over 2 million people are hospitalised and 100,000 die each year from ADR.

The reason for this differential of action is due to a person’s specific genetic make up which allows for a difference in how a drug is metabolised. The new discipline of pharmacogenomics investigated this all too important interaction between a putative pharmacological agent and persons genome. The underlying aim of pharmacogenomics would be to tailor a drug to a person’s genes, ushering in the era of personalized medicine.

The development of pharmacogenomics as a routine part of drug discovery will generate large and sustainable revenues for the drug industry - BUT HOW MUCH? Find out by reading this exclusive report.

There are other aspects to pharmacogenomics which includes the technical part of this new discipline: such as
* Bioinformatics
* DNA Microarrays

It will provide a detailed analyses of these markets including, revenues, growth rates, companies involved and new developments.

Complete with tables, news, insights, the latest developments and a complete survey of the pharmacogenomics market and research arena. Pharmacogenomics will most likely become the dominant drug discovery method in years to come and you and your organisation should be part of it.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44662
_______________________________________________________________

The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% market share. However, in 2006 Ambien loses its patent protection, and the sleep disorder market looks set for dramatic growth and the introduction of at least four new products. In April 2005 year the first real competition for Ambien arrived on the market in the form of Estorra from Sepracor.

The purpose of this market report is to examine the factors that will influence the market and examine why It has a forecast for the market to grow to over $4.4 billion by 2010. The imminent pipeline products are examined in detail and their potential strengths and weaknesses compared. The futures of the older products are assessed. Non-product related factors are considered as the insomnia treatment market has attracted considerable negativity associated with poor side effects and in particular dependency.

The potential for market growth is enormous with only 10% of the estimated potential patient population of 150 million using prescribed pharmaceutical products for insomnia. Although insomnia is by far the most common sleep disorder, this report also considers the markets for:

Narcolepsy
Restless Leg Syndrome (RLS)
Obstructive Sleep Apnea (OSA).

Sanofi-Aventis is the leading company in the sleep disorder market, but over 25 companies are mentioned in this report. The report assesses which companies and products will be key companies by 2010.

Why you should buy this report :

It is a market that will more than double in size by 2010.
It is a market that will change from one dominant product to one with at least 5 key products.
Characteristics of an ideal sleep disorder treatment are compared with the current and pipeline products.
Ambien is key product for Sanofi-Aventis and is at a pivotal point in its life cycle. How this will affect the future sales levels for Sanofi-Aventis is assessed.
Sanofi-Aventis and Sepracor have significantly increased their level of DTC advertising. The importance of this and other non-product related factors are considered.

For anyone with or considering involvement with the sleep disorder market this report is the most recently published report to examine and consider all of the salient factors.

Companies Mentioned in This Report :

Alliance Pharma, Arena Pharmaceutical, Astellas, Celgene, Cephalon, Eli Lilly, Fujisawa Pharmaceutical
GSK, King Pharmaceuticals, Lundbeck, Merck, Merck KgaA, Neurocrine Bioscience, Neurogen, Novartis
Organon, Orphan, Pfizer, Sanofi-Aventis, Sepracor, Shering AG, Shire, Somaxon, Takeda, Pharmaceutical, Teva, Wyeth/Elan, Yamanouchi

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44669
_______________________________________________________________

In 2004 total world revenues for branded antidepressant drugs was worth over $13bn, but with only ten drugs on the market. However, nine out of these ten drugs faces a loss of patent in the period 2006-2010.  

Table of Contents :

1. Executive Summary
1.1 Aims And Scope of Antidepressants, 2006

2. Introduction
2.1 The Global Cost of Depression
2.2 Overview of the Global Antidepressant Market
2.2 The Threat of Generics

3. Disease Background and Treatment Options
3.1 What Is Depression?
3.2 Different Types Of Depression
3.2.1 Major Depressive Disorder (MDD)
3.2.2 Dysthymia
3.2.3 Bipolar Disorder Is Not Depression
3.2.4 Other Types Of Depression
3.3 Causes Of Depression
3.4 Age, Sex and Depressive Disorders
3.4.1 Depression In Women
3.4.2 Depression In Men
3.4.3 Depression In The Elderly
3.5 The Receptor Hypothesis Of Depression
3.5.1 Serotonin
3.5.2 Norepinephrine (Noradrenaline)
3.5.3 Dopamine
3.5.4 Targets For Drug Development
3.6 Anxiety
3.7 Drug Therapies For Depression
3.7.1 Monoamine Oxidase Inhibitors (Maois)
3.7.2 Tricyclic Antidepressants (TCAs)
3.7.3 Selective Serotonin Re-Uptake Inhibitors
3.7.4 Selective Serotonin and Norepinephrine Re-Uptake Inhibitors
3.7.5 Selective Catecholamine Reuptake Inhibitors
3.8 Leading Drugs In The Antidepressant Market and Their Mode Of Action

4. World Antidepressant Market, 2005-2010
4.1 World Revenue Forecast For Leading Antidepressants
4.2 Market Share by Drug
4.3 Patent Issues and Generic Encroachment
4.4 More Sophisticated Marketing is Required to Drive the Market
4.4.1 Regulatory Restraints Limit Marketing Options
4.4.2 Tapping the Untapped - Can Antidepressant Uptake be Increased by Marketing?
4.4.3 New Indications and Off-Label Use Can Extend an Antidepressant’s Lifetime
4.4.4 Compliance is a Major Concern
4.4.5 New Formulations Will Provide a Small Amount of Protection from Generics
4.4.6 Pricing
4.5 The Psychology of Drug Prescription
4.6 SSRIs Dominate But Will Lose their Majority Market Share by 2010
4.7 SSNRIs Will Increase Their Market Share
4.8 Other Modes of Action Should Hold their Market Share But May Lose Out to New Treatments
4.9 Individual Forecasts For SSRIs
4.9.1 Zoloft (Pfizer)
4.9.2 Paxil/Seroxat (GSk)
4.9.3 Lexapro And Celexa (Lundbeck A/S and Forest Laboratories)
4.9.4 Prozac (Lilly)
4.9.5 Luvox (Astellas Pharma)
4.10 Effexor Is Well-Established But Faces a Challenge from Cymbalta
4.10.1 Effexor (Wyeth)
4.10.2 Cymbalta (Lilly)
4.11 Other Classes of Antidepressants
4.11.1 Wellbutrin (GSK)
4.11.2 Remeron (Azko Nobel)
4.12 The Antidepressant Market Will Become Extremely Dynamic Because of the Next Generation of Therapies

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44671
_______________________________________________________________

Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise.

At present, the pharmaceutical prescription market to treat GI disorders market is valued at just over $20 billion, reflecting that it is one of the largest and most important therapeutic areas in the pharmaceutical industry. It has just produced a business intelligence report, Gastrointestinal Disorders 2007-2012, which addresses the state of this market, and assesses how it will develop in the future. Are you involved in this market area? Will the future of this market affect your business?

AstraZeneca’s Nexium is currently the most successful GI drug available in the market, based on sales revenues totaling more than $6 billion. What is the future for Nexium? How will its impact shape the GI market? Will other GI drugs reach blockbuster status? If so, which ones? Find out in this vital report.

Another example of change in the GI market is the withdrawal of Novartis’s from the US market, due to safety and efficacy issues. What effects will this have on the other GI drugs? How will this affect the overall GI market? What does the future hold for Novartis and Zelnorm? These are all crucial questions that need answers, which can be found by buying this It report.

It’s World Gastrointestinal Disorders report includes three major classes of product which It believes will extensively occupy the GI market. These are:

Proton Pump Inhibitors  (PPIs)
Histamine H2 Receptor Antagonists
Other Leading GI agents
Which new drugs will be marketed? Which drugs will have the most impact on the market? Most importantly, what are the future prospects of the GI market?

The following crucial aspects of the GI market are discussed :

The current world GI market
SWOT Analysis of the GI market
Revenue Forecasts for all the drugs analysed 2007-2012
Market Activity
Geographical breakdown of GI market
Potential treatment population forecasted to 2012 for major leading global markets
Discussion on comparative pricing of the major GI drugs
Analysing the major generic/substitute products
Detailed information on pipeline products
Discussion on possible future strategies in GI market 
Why You Must Buy This Report:

This 180+ paged report features 47 figures which includes graphs and charts, 28 tables, insight, and include the latest developments in the gastrointestinal market with up-to-date analysis.

This report will give you the understanding you require to gain that competitive edge in the GI market. This large revenue producing therapeutic area is in the top ten of the largest earning revenues in the pharma industry. Therefore, it is vital that the latest gastrointestinal report is brought without fail.

The revenue forecasts generated in this report are highly accurate and are determined by the market and its future prospects in terms of patent protection, generic competition, life-cycle management, licensing agreements and market activity. The forecast runs up to 2012. Therefore it gives your company sound understanding of how GI drug will behave up until that time.

Key questions that this report answers:

What are the most influential GI disorders and their impacts?
Which drugs are dominating their classes in the GI market?
What is the revenue potential in 2012 for these drugs?
What market activity is occurring? (What are pharma companies doing?)
What is the potential population treatment in the major global markets up to 2012?
Which is the status of the GI pipeline?

Unique benefits to you when you order this report :

- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using hard drive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=46979
_______________________________________________________________